Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Clinical Chemistry

Background:

• Clopidogrel is a P2Y12 receptor inhibitor crucial for preventing cardiovascular events in acute coronary syndromes.
• Variable patient response to clopidogrel, often due to cytochrome P450 (CYP) enzyme efficacy, necessitates personalized treatment approaches.
• Tailored regimens aim to optimize antiplatelet response by identifying and managing poor responders.

Purpose of the Study:

• To evaluate the current clinical utility of tailored clopidogrel treatment strategies.
• To assess the reliability and standardization of diagnostic methods used for clopidogrel response assessment.

Main Methods:

• Review of laboratory tests for platelet function (e.g., aggregometry, vasodilator-stimulated phosphoprotein phosphorylation assay, VerifyNow P2Y12 assay).
• Analysis of cytochrome P450 (CYP) genotyping for predicting clopidogrel metabolism.
• Assessment of current guidelines and evidence for tailoring clopidogrel therapy.

Main Results:

• Significant discordance exists among platelet function tests in identifying poor clopidogrel responders.
• Lack of standardization and clear guidance for interpreting and acting upon test results.
• CYP genotyping explains only a small fraction (approx. 10%) of individual variability in clopidogrel response.

Conclusions:

• Current platelet function tests and CYP genotyping lack the necessary standardization and predictive accuracy for routine clinical implementation of tailored clopidogrel therapy.
• Further research and development are required to establish reliable methods for personalized clopidogrel treatment to prevent cardiovascular events effectively.